Technical feasibility of [
Animals
Brain Neoplasms
/ metabolism
Cell Line, Tumor
Disease Models, Animal
Feasibility Studies
Female
Glioblastoma
/ metabolism
Nitroimidazoles
/ metabolism
Positron-Emission Tomography
Radiopharmaceuticals
/ metabolism
Radiotherapy Dosage
Radiotherapy, Image-Guided
/ methods
Rats, Inbred F344
Treatment Outcome
Tumor Burden
Tyrosine
/ analogs & derivatives
FAZA
FET
Glioblastoma
PET boosting
Preclinical
Radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
30 May 2019
30 May 2019
Historique:
received:
27
11
2018
accepted:
08
05
2019
entrez:
1
6
2019
pubmed:
31
5
2019
medline:
27
11
2019
Statut:
epublish
Résumé
Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part. F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm When comparing the dose volume histograms, a significant difference was found exclusively between the D In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part.
METHOD
METHODS
F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm
RESULTS
RESULTS
When comparing the dose volume histograms, a significant difference was found exclusively between the D
CONCLUSION
CONCLUSIONS
In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory.
Identifiants
pubmed: 31146757
doi: 10.1186/s13014-019-1290-4
pii: 10.1186/s13014-019-1290-4
pmc: PMC6543630
doi:
Substances chimiques
Nitroimidazoles
0
Radiopharmaceuticals
0
(18F)fluoroethyltyrosine
1326R5J1IA
fluoroazomycin arabinoside
1QR3UU6P48
Tyrosine
42HK56048U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
89Références
Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):551-60
pubmed: 10837935
J Clin Oncol. 2002 Mar 1;20(5):1375-82
pubmed: 11870182
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):511-9
pubmed: 16168843
Cancer Imaging. 2007 Jun 11;7:104-16
pubmed: 17594916
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Nucl Med. 2008 Jan;49(1):1-4
pubmed: 18077528
Cancer Imaging. 2004 Mar 26;4(2):68-73
pubmed: 18250011
Cancer Imaging. 2004 Oct 21;4(2):153-61
pubmed: 18250025
J Clin Neurosci. 2008 May;15(5):545-51
pubmed: 18378459
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Nature. 2009 Feb 5;457(7230):675-7
pubmed: 19194443
Cancer Immunol Immunother. 2009 Oct;58(10):1627-34
pubmed: 19221744
J Neurooncol. 2009 Sep;94(3):299-312
pubmed: 19381449
Cancer Treat Rev. 2009 Dec;35(8):714-23
pubmed: 19767151
Br J Cancer. 2010 Aug 10;103(4):498-504
pubmed: 20628383
Radiother Oncol. 2010 Sep;96(3):280-7
pubmed: 20724013
Appl Radiat Isot. 2011 Dec;69(12):1717-20
pubmed: 21458282
ASN Neuro. 2011 Aug 03;3(3):e00063
pubmed: 21740400
Hematol Oncol Clin North Am. 2012 Aug;26(4):825-53
pubmed: 22794286
Nucl Med Biol. 2013 Aug;40(6):831-40
pubmed: 23915802
PLoS One. 2014 Apr 23;9(4):e95830
pubmed: 24759867
J Neurooncol. 2014 Nov;120(2):257-66
pubmed: 25069566
Nucl Med Biol. 2015 Jan;42(1):38-45
pubmed: 25218024
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):877-85
pubmed: 25257812
Med Phys. 2014 Oct;41(10):102701
pubmed: 25281980
Br J Radiol. 2015 Jul;88(1051):20150056
pubmed: 25827209
Med Phys. 2015 Apr;42(4):1710-20
pubmed: 25832060
Radiat Res. 2015 May;183(5):501-10
pubmed: 25897556
Clin Cancer Res. 2015 Dec 15;21(24):5511-8
pubmed: 26276892
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1144-53
pubmed: 26876954
Expert Opin Pharmacother. 2016 Jun;17(9):1259-70
pubmed: 27052640
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
PLoS One. 2016 Aug 25;11(8):e0161845
pubmed: 27559736
Acta Neuropathol. 2017 Feb;133(2):263-282
pubmed: 28074274
J Neurooncol. 2017 Jul;133(3):455-467
pubmed: 28527008
Acta Oncol. 2017 Sep;56(9):1181-1188
pubmed: 28537761
Med Phys. 2017 Sep;44(9):4795-4803
pubmed: 28626876
Med Phys. 2017 Sep;44(9):4786-4794
pubmed: 28627007
J Vis Exp. 2017 Dec 28;(130):
pubmed: 29364211
Radiat Oncol. 2018 May 10;13(1):89
pubmed: 29747666
Front Med (Lausanne). 2019 Jan 29;6:5
pubmed: 30761302
Sci Rep. 2019 Feb 27;9(1):2878
pubmed: 30814660
Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1041-52
pubmed: 7493830